45 results about "Potential biomarker" patented technology

The invention discloses an immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 and application thereof, and belongs to the field of microbial animal cell lines. The immortalized human pelvic kidney cancer related fibroblast line is named as RPCcaf-X1, and the preservation number of the immortalized human pelvic kidney cancer related fibroblast line is CCTCC (China Center For Type Culture Collection) NO: C2025306. The invention also discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in the research of the pathogenic mechanism of the pelvis and kidney cancer. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in tumor microenvironment research. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in drug screening or research and development. The invention further discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in screening of potential biomarkers related to pelvis and kidney cancer.

The application belongs to the technical field of biological detection, and discloses a screening method of respiratory tract infection related biomarkers based on macro-transcriptomics. The application performs macro-transcriptome sequencing on respiratory tract infection samples with different clinical phenotypes, performs data quality control, alignment, transcript quantification, retains pathogen and host information, and then identifies genes stably expressed or significantly changed in different groups by combining differential expression analysis and co-expression analysis, obtains potential biomarkers, and obtains the biomarkers by taking the intersection genes of three machine learning algorithms of LASSO algorithm, random forest model and SVM model. The application provides a screening method of biomarkers for rapid and accurate identification of respiratory tract infection.

A method for early diagnosis of autism spectrum disorder (ASD) including determining an ASD risk index, determining an ASD brain index that includes administering at least one auditory brainstem response (ABR) test to an ear canal of a patient, producing a plurality of biomarkers and identifying at least one biomarker of the plurality of biomarkers as a potential ASD biomarker, and determining an ASD likelihood responsive to each of the ASD risk index and ASD brain index.

The application discloses a breast cancer examination tool based on collagen fiber multi-element fusion analysis, which is used for quantitative analysis of breast tissue collagen fiber structure characteristics and examination of breast tissue cancer level. The application can multidimensionally and comprehensively extract structure information of collagen fibers, and through multi-element fusion analysis of multiple structure parameters, the application improves information complementarity of breast tissue morphological characteristic analysis; the application realizes visualization of collagen fiber structure characteristics by using a pixel level resolution quantitative method and combining with a pseudo-color coding technology, and enhances intuitiveness of information; the application classifies and analyzes three potential biomarkers representing different breast cancer levels, provides a high-precision, automatic and rapid breast cancer level examination method, and has greater application potential compared with a traditional breast cancer examination method.

The invention relates to the technical field of biomedicine, in particular to application of CCN2 serving as a target spot to preparation of a medicine for diagnosing, preventing and / or treating anti-phospholipid syndrome. The invention provides application of CCN2 serving as a biomarker to diagnosis of APS and other related vasculopathy, application of CCN2 serving as a treatment target to preparation of drugs for preventing and / or treating anti-phospholipid syndromes and an establishment method of an APS related vasculopathy model. According to the invention, it is found for the first time that CCN2 targets in APS blood vessels play a crucial role in promoting proliferation and migration of vascular endothelial cells and vascular smooth muscle cells, a new perspective is provided for knowing cell and molecular mechanisms of vasculopathy, and it is determined that CCN2 can be used as a potential biomarker for diagnosing APS vasculopathy and evaluating disease progression of APS vasculopathy. And potential targets for clinical anti-proliferation treatment.

The application discloses a three-dimensional DNA walker biosensor based on SERS as well as a preparation method and application thereof, relates to the technical field of biosensors, and is used for detecting target lncRNA. The biosensor comprises an MB\@DNA\@Au\@Ag compound, a 3D DNA walker and an aptamer. The nucleotide sequence of the ssDNA linker is shown in SEQ ID NO:1. The nucleotide sequence of the 3D DNA walker is SEQ ID NO:7 or SEQ ID NO:8 or a corresponding reverse complementary sequence. The biosensor realizes isothermal autonomous walking of the three-dimensional DNA walker and releases MGITC coded Au@Ag SERS nanolabels through TapSAKI triggered strand displacement and Nb.BbvCI enzymatic cleavage, thereby generating a'signal-on' type Raman output. The detection limit of the biosensor for the AKI early diagnosis potential biomarker TapSAKI is as low as 1.16 fM, and reliable quantification can be realized in the range of 4.30-850 fM. Compared with RT-qPCR (LOD is about 0.26 pM), the biosensor is improved by about 2.3 orders of magnitude in the detection limit of molar concentration.

This invention discloses a set of biomarkers, reagents, kits, and applications for predicting alcoholic liver disease (ALD), belonging to the field of biomarker technology. The key technical points are: This invention uses non-target metabolomics to analyze plasma from ALD patients and healthy controls to identify potential biomarkers and related metabolic pathways in the plasma of ALD patients. Through human fecal metagenomic sequencing, potential biomarkers in the microbiome of ALD patients are identified, providing a scientific basis for the pathogenesis and early screening of ALD. Furthermore, this invention evaluates the therapeutic effect of L-threonine on ALD and explores its molecular mechanism, providing solid preclinical evidence and theoretical basis for L-threonine as a safe and effective natural metabolite-derived drug for the treatment of ALD, opening new directions for the development of innovative ALD therapies.

The invention belongs to the technical field of biology, and relates to application of a reagent for detecting LOX gene G473A polymorphism in preparation of a kit for predicting epilepsy susceptibility. In a correlation test, the LOX G473A gene polymorphism shows good diagnostic performance (AUC is equal to 0.8143, sensitivity is equal to 74.29%, and specificity is equal to 88.57%) in the aspect of predicting epilepsy susceptibility, and still keeps a good discrimination level (AUC is equal to 0.8158, sensitivity is equal to 84.21%, and specificity is equal to 78.95%) in a verification test, so that the LOX G473A polymorphism can be used as a potential biomarker for clinical diagnosis of epilepsy diseases.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The application relates to a screening and determining method of an ischemic cerebral stroke animal model biomarker of qi deficiency and blood stasis syndrome, which integrates proteomics and transcriptomics technologies, systematically screens differentially expressed proteins and genes related to the syndrome, and on the basis, constructs various disease animal models, verifies candidate targets by adopting ELISA, simultaneously combines qPCR technology, multi-dimensionally confirms expression changes in the models, further draws ROC curves, calculates AUC values, sensitivity and specificity and other diagnostic performance indexes, evaluates diagnostic potential, and further knocks down and overexpresses differentially expressed genes, deeply excavates potential biomarkers with diagnostic values, and provides scientific bases for objective diagnosis of ischemic cerebral stroke qi deficiency and blood stasis syndrome and exploration of molecular mechanisms.

The invention discloses application of a deubiquitinating enzyme STAMBPL1 as a pancreatic cancer diagnostic kit and in targeted drug development. According to the research, by mining a TCGA-PAAD public data set of a TCGA database, the transcriptome expression level of STAMBPL1 in pancreatic cancer tissue is found to be remarkably higher than that in normal tissue. The research also finds that the proliferation and migration of the human pancreatic cancer cell line PANC-1 can be inhibited in vitro by knocking down the STAMBPL1 through the small interfering RNA, and the mRNA level expression quantity of tumor proliferation and cell cycle related genes is reduced. According to the expression difference of the STAMBPL1 in pancreatic cancer derived from a patient and normal tissue and the experimental results of cell phenotype and gene transcription level expression detection after knockdown, the STAMBPL1 can be possibly used as a potential biomarker of pancreatic cancer and a potential target of a pancreatic cancer diagnostic kit.

This invention discloses the application of a substance for detecting piRNA biomarkers, including one or more of the following applications: A1) application in the preparation of products for diagnosing myocardial aging; A2) application in the preparation of products for screening myocardial aging; A3) application in the preparation of products for treating myocardial aging; A4) application in the preparation of products for assessing the condition of myocardial aging; A5) application in the preparation of products for differentiating myocardial aging from other diseases; the piRNA biomarker is piR-hsa-014388, and its nucleotide sequence is shown in SEQ ID No. 1. The piR-hsa-014388 biomarker provided by this invention shows a significantly higher expression level in the plasma of patients with myocardial aging than in healthy controls, indicating that piR-hsa-014388 is a potential biomarker for myocardial aging. The ROC curve of piR-hsa-014388's efficacy in diagnosing patients with myocardial aging shows that piR-hsa-014388 has good diagnostic efficacy.

The application discloses a state-related convolution sparse model-based electroencephalogram signal pattern recognition method, aiming at the problem that existing convolution sparse coding is difficult to recognize state-related biomarkers, state-shared and state-specific waveforms are used for modeling, and the waveform characteristics of electroencephalogram signals in different states are clearly distinguished. Based on this, the application adopts waveform inconsistency constraints to efficiently identify potential biomarkers related to certain states, and the identified potential biomarkers have good interpretability and can be used as an effective tool for auxiliary medical diagnosis.

The invention discloses a hypothalamic malocroma epilepsy subtype identification method based on an interpretable graph neural network, and belongs to the technical field of epilepsy diagnosis. The method comprises the following steps: acquiring a preoperative electroencephalogram signal of a hypothalamic malocclusion accompanied with epilepsy patient, and performing preprocessing and feature extraction to obtain time-frequency feature data; the method comprises the following steps of: firstly, acquiring a spatial topology feature, a multi-scale time-frequency feature and a dynamic time sequence feature of brain function connection through a main layer, a graph attention network module, a multi-scale frequency-time attention module and a bidirectional long-short-term memory network, and realizing subtype identification of the sphincter epilepsy and the non-sphincter epilepsy by cooperatively capturing the spatial topology feature, the multi-scale time-frequency feature and the dynamic time sequence feature of brain function connection; and finally, extracting an adjacent matrix after training convergence of the GAT module, and mining potential biomarkers through network topology quantitative analysis. The method breaks through the limitation of traditional subjective identification, improves the identification accuracy and stability through a multi-module collaborative architecture, provides an objective basis for clinic, and has an important clinical conversion value.

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

The application discloses a biomarker, a kit and application for diagnosing ventricular repolarization prolongation caused by cold exposure, and comprises one or more of the following applications: A1) application in preparing a product for diagnosing ventricular repolarization prolongation caused by cold exposure; A2) application in preparing a product for screening ventricular repolarization prolongation caused by cold exposure; A3) application in preparing a product for treating ventricular repolarization prolongation caused by cold exposure; A4) application in preparing a product for evaluating ventricular repolarization prolongation caused by cold exposure; A5) application in preparing a product for distinguishing ventricular repolarization prolongation caused by cold exposure from other heart diseases; and the miRNA marker is hsa-miR-125b-5p, and the nucleotide sequence is shown as SEQ ID No. 1. The expression amount of the hsa-miR-125b-5p marker provided by the application in the plasma of a ventricular repolarization prolongation caused by cold exposure group is significantly higher than that of a control group, has good diagnostic efficiency for ventricular repolarization prolongation caused by cold exposure, and indicates that the hsa-miR-125b-5p is a potential biomarker for ventricular repolarization prolongation caused by cold exposure.

The invention provides application of 73rd histidine methylation of serum actin as a marker in preparation of a reagent for assisting early prognosis evaluation of sepsis, and belongs to the technical field of biomarkers. Tests show that the 73rd site histidine of serum actin is subjected to methylation modification, and the differences among a Control group, a Survivor group and a Non Survivor group are remarkable; the secondary spectrum of the target peptide fragment shows that the peptide spectrum matching effect of the modified peptide fragment is good, and the modification identification is credible; and the area under the ROC curve and the 95% confidence interval are 73.56% (60.17%-82.68%). Under the optimal cutoff value of 30.29, the sensitivity is 0.792, the specificity is 0.639, the positive predicted value is 0.656, the negative predicted value is 0.780, the positive likelihood ratio is 2.198, and the negative likelihood ratio is 0.325. Therefore, the 73 histidine methylation of serum actin is an independent predictive factor of sepsis prognosis, can be used as a reliable and potential biomarker for early prognosis evaluation of sepsis, and has important clinical application value.

Cumulus cell (CC) gene expression is explored as an additional method of morphological scoring to select an embryo with the highest chance of pregnancy. The present invention relates to a novel method for identifying biomarker genes for assessing the ability of mammalian oocytes to produce viable pregnancy after fertilization based on the use of live birth and embryonic development as endpoint criteria for the oocytes for exon level analysis of potential biomarker genes. The invention further provides biomarker genes of CC expression thus identified, as well as prognostic models based on biomarker genes identified using the methods of the invention.

The invention relates to a maintenance hemodialysis patient death risk prediction model based on a plasma amino acid spectrum and construction and application of the model, and belongs to the technical field of biological medicine. The construction method comprises the following steps: detecting a baseline plasma sample of a maintenance hemodialysis patient through a Bruker nuclear magnetic resonance spectrometer; a cox proportional risk model is adopted to perform correlation analysis on each amino acid, and after important clinical covariables are corrected, it is determined that eight amino acid parameters are significantly related to the total cause death rate; obtaining a p value lt through a cox proportional risk model; the method comprises the following steps of: taking a parameter of 0.05 as a candidate parameter, screening potential biomarkers by adopting a support vector machine algorithm in combination with conventional clinical parameters which are proved to be related to hemodialysis patient prognosis, and constructing and obtaining a prediction model by adopting a logistic regression model according to the screened parameters; through the model provided by the invention, the patient death risk prediction capability is remarkably improved.

The invention discloses a metabonomics data analysis method and system, and the method comprises the steps: obtaining metabonomics data of a biological sample under multiple conditions, and carrying out the filling of missing values through employing a data distribution characteristic fusion strategy; calculating a response intensity distribution difference value of each metabolite feature through sliding window local fluctuation analysis, and screening candidate difference metabolite features; sequencing the response values of the features under different conditions according to the size and fitting the response values into a feature response curve, and clustering by calculating the similarity of the curve to obtain a feature cluster; further, on the basis of the collaborative change intensity between the overall form and local synchronism fusion measurement features, a weighted network is constructed, community division is carried out, feature pairs with high collaborative intensity are screened from all sub-communities, and a potential biomarker combination is formed. According to the method, the whole-process analysis from data reconstruction, difference screening to collaborative marker identification is realized, and the accuracy, robustness and biological interpretability of single-sample metabonomics data mining are improved.

The invention relates to a tissue marker for proton radiation heart injury and application of the tissue marker. The tissue marker comprises one or more of a transcription marker and a protein marker. Wherein the transcription marker comprises one or more of PIK3R5, CCR7, IL7R, CD7, CD22, CR2, CCL5 and VAV1, and the transcription marker comprises one or more of PIK3R5, CCR7, IL7R, CD7, CD22, CR2, CCL5 and VAV1; and the protein marker comprises one or more of SIRT1 and HMGB1 (High Mobility Group Box 1). According to the invention, the differential marker is used as a potential biomarker of the radioactive heart loss, and a research method for researching the radioactive heart loss by using a mouse model is provided, so that a demonstrative research is provided for multi-omics analysis of the radioactive heart loss and explanation of an action mechanism of the radioactive heart loss.

The invention provides application of Ackermania muciniphila as a biomarker in preparation of a product for diagnosing and / or treating atherosclerosis, and belongs to the technical field of biological medicines. The invention provides an application of Akkermansia muciniphila (Akkermansia muciniphila) as a biomarker in the preparation of a kit for diagnosing and / or detecting atherosclerosis (AS). The Akkermansia muciniphila can be used for detecting atherosclerosis (AS). A high fat diet induced ApoE gene knockout mouse copies an AS mouse model, metagenomics analysis of a control group and a model group shows that the abundance difference of Ackermania muciniphila is significant, and the AUC value under an ROC curve is 1, which indicates that Ackermania muciniphila is a potential biomarker strain of AS. The Ackermania muciniphila can also significantly reduce the AS plaque area of the aortic sinus of the AS model mouse, and the Ackermania muciniphila can play an anti-AS role through a two-component system, ABC transport and other metabolic pathways.

The invention discloses an application of IGFBP2 as a biomarker and a therapeutic target of diabetic nephropathy podocyte apoptosis, an application of an IGFBP2 specific gene inhibitor in preparation of drugs for treating diabetic nephropathy podocyte apoptosis and a method for in-vitro non-therapeutic inhibition of diabetic nephropathy podocyte apoptosis, and relates to the technical field of biological pharmacy. According to the technical scheme, the molecular marker can be effectively used for screening diabetic nephropathy, has high diagnostic value in distinguishing diabetes mellitus and diabetic nephropathy stages, can be used as a potential biomarker for early diagnosis of diseases, and can successfully inhibit apoptosis of diabetic nephropathy podocytes in experimental samples.

The invention belongs to the technical field of molecular diagnosis and immunotherapy, and particularly relates to a group of biomarkers and application thereof in diagnosis of immune-mediated necrotizing myopathy. The invention firstly provides a group of biomarkers for predicting, treating or diagnosing immune-mediated necrotizing myopathy, and the biomarkers are protein markers, and comprise one or a combination of more than two markers selected from CSRP3, HSP90AB1, MYH1, ITGB1BP2, SMPX, MYBPC2, CD9, ICAM1, ANKRD1 and NT5C1A. The invention also provides application of the marker in preparation of a product for predicting, treating or diagnosing immune-mediated necrotizing myopathy. Through muscle proteomics analysis, a unique and shared way in anti-SRP and anti-HMGCR myopathy is disclosed, and it is determined that HSP90AB1, ITGB1BP2, CD9, ICAM1 and ANKRD1 are potential biomarkers for the severity of IMNM diseases. These findings provide valuable insights for the determination of pathogenesis and therapeutic targets of IMNM.

The present application provides a kind of based on PBA data's microorganism structure proteomics analysis method, by inputting the PBA original data of microorganism structure, extract the encoding nucleotide fragment containing specific information from the PBA original data, obtain intermediate transmission data;Then extract the protein expression data of the microorganism structure from the intermediate transmission data.From protein expression data, the total protein expression data of sample, the protein combination data of multiple protein co-expression, the subgroup data obtained after clustering analysis based on the protein expression data of the microorganism structure are analyzed to obtain machine learning.In the multi-level of protein expression, protein combination, subgroup, potential biomarker screening can be carried out.The analysis method described in the present application analyzes the total protein expression, protein combination form, microorganism structure subgroup and its protein fingerprint characteristics and quantification on the level of single microorganism structure, fills the blank of bioinformatics analysis in the field of microorganism structure proteomics detection.

The present application relates to the field of biotechnology, in particular, the application of E4BP4 in hematological diseases such as multiple myeloma. The present application proves that E4BP4 can be used as a potential biomarker and prognostic indicator for predicting the development of multiple myeloma, which is helpful for the treatment of multiple myeloma. Moreover, the E4BP4 protein can be used in the preparation of MM promoting reagents, which can be further used in the amplification of MM cells, the preparation of MM tumor metastasis models, the screening of MM treatment drugs and the like. After knocking down E4BP4, autophagy is induced and MM cell apoptosis is promoted, thereby enhancing the anti-myeloma effect of dexamethasone on MM. E4BP4 inhibitory drugs can be used as anti-myeloma drugs together with dexamethasone.

The invention discloses an inhibitory lactic acid site of SOD1 protein and application of the inhibitory lactic acid site, and the site is the 123 lysine of wild type SOD1 protein with an amino acid sequence as shown in SEQ ID NO.1, namely K123. The method has high specificity, high sensitivity and repeatability, the screened SOD1-K123 lactoacylation site can be used as a potential biomarker for IVDD diagnosis and a potential target for treatment, and a new technical direction and an experimental basis are provided for precise diagnosis and treatment of IVDD.

The invention discloses a biomarker for diagnosing ankylosing spondylitis. The biomarker is G6PD in a human peripheral blood mononuclear cell. The invention utilizes microarray analysis to detect differentially expressed mRNA in peripheral blood mononuclear cells, and confirms that these candidate mRNAs are indeed different and can be used as potential biomarkers for diagnosis of ankylosing spondylitis. The result shows that the expression change of the G6PD in the peripheral blood mononuclear cells of an ankylosing spondylitis patient can be used as a marker for diagnosing the ankylosing spondylitis, which is beneficial to exploring the pathogenesis of the disease, provides a new direction for the diagnosis of the ankylosing spondylitis and has a wide clinical application prospect.

The invention relates to a proton radiation brain injury tissue marker and application thereof, radiation brain injury differential metabolite markers comprise prostaglandin F2alpha, fructose-1, 6-diphosphate, dihydroxyacetone phosphate and inosine, and differential protein markers comprise fibroblast growth factor receptor 2 and calcium / calmodulin dependent protein kinase II. Differential metabolites and differential proteins are used as proton radiation brain damage biomarkers. According to the invention, the differential marker is used as a potential biomarker of radiation brain tissue injury, and demonstrative research is provided for multi-omics analysis of radiation brain injury and explanation of an action mechanism of radiation brain injury.

The invention discloses a metabonomics technology-based bean pulp mildew detection method, and belongs to the technical field of food quality detection. According to the method, the problems of high subjectivity and long consumed time in the prior art are solved, and metabolite characteristics highly related to the mildew degree are screened out from different angles through correlation analysis and mutual information methods; dimensionality reduction processing is effectively carried out on feature information through a principal component analysis method so as to reduce the complexity of data; by calculating a variable importance projection VI P value, a variable which contributes to a principal component most can be identified, and a potential biomarker is extracted; by calculating the t test P value, significant difference variables can be further screened, and the false positive rate is controlled by adopting a Bonferron i correction method, so that a comprehensive mildew detection process is formed, effective input characteristic data is provided for a discrimination model, and powerful support is provided for quality control and mildew prevention of soybean meal.